Stockscreener 앱 받기
285.04
1.07%
3.03
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Activity Recap: Will Krystal Biotech Inc outperform small cap indexes2025 Institutional Moves & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Krystal Biotech (KRYS) Price Target Increased by 18.96% to 269.93 - Nasdaq
Krystal Biotech (BIT:1KRYS) Price Target Increased by 19.80% to 226.45 - Nasdaq
Movement Recap: What is Krystal Biotech Inc.’s market position2025 Short Interest & Daily Profit Maximizing Tips - baoquankhu1.vn
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - sharewise.com
Citigroup Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price - MarketBeat
Avoiding Lag: Real-Time Signals in (KRYS) Movement - Stock Traders Daily
Krystal Biotech stock maintains Buy rating at H.C. Wainwright on strong revenue - Investing.com Canada
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
Credo Technology Group Holding And 2 Insider Picks For Strong Growth - Yahoo Finance
Krystal Biotech Reports ~$389M 2025 VYJUVEK Revenue, $955M Cash Reserves - Nasdaq
Krystal Biotech expects Vyjuvek net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Rpt-Krystal Biotech Expects VYJUVEK Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Krystal Biotech Announces Preliminary 4Q 2025 VYJUVEK Revenue of $106-$107 Million and Strategic Vision for Growth in Rare Disease Market - Quiver Quantitative
Krystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Krystal Biotech expects net revenue of $106 million to $107 million for Q4 2025 - marketscreener.com
Krystal Biotech Expects Net Revenue Of $106 Million To $107 Million For Q4 2025 - TradingView — Track All Markets
Inside one company's plan to reach 10,000 rare disease patients - Stock Titan
Krystal Biotech rises on new phase 1 data for cystic fibrosis asset - MSN
Krystal Biotech Reports $107M VYJUVEK Revenue for Q4 2025 - Intellectia AI
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Data And FDA Study Filing - Yahoo Finance
Is Krystal Biotech (KRYS) Still Attractively Priced After Its Strong Multi Year Share Price Run - Yahoo Finance
Krystal Biotech (NASDAQ:KRYS) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
KRYS: TD Cowen Raises Price Target and Maintains Buy Rating | KR - GuruFocus
Assessing Krystal Biotech (KRYS) Valuation After Positive KB407 Cystic Fibrosis Trial Update - Yahoo Finance
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Krystal Biotech (KRYS) Rises on Positive Phase 1 Data for Cystic Fibrosis Treatment - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Stock Price Up 7%Still a Buy? - MarketBeat
Krystal Biotech stock price target raised to $306 by TD Cowen on CF data - Investing.com Canada
Krystal Biotech stock hits all-time high at 265.99 USD By Investing.com - Investing.com Canada
Citigroup Raises Price Target for Krystal Biotech (KRYS) to $320 - GuruFocus
Krystal Biotech stock hits all-time high at 265.99 USD - Investing.com India
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com Nigeria
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why - Yahoo Finance
Krystal Biotech stock maintains Overweight rating at Cantor Fitzgerald - Investing.com
Krystal Biotech stock price target raised to $288 from $272 at BofA - Investing.com Canada
Aug Momentum: Will Krystal Biotech Inc. stock reach all time highs in 2025 - Улправда
KRYS: HC Wainwright & Co. Raises Price Target to $310 | KRYS Sto - GuruFocus
Krystal Biotech (NASDAQ:KRYS) Upgraded by Zacks Research to Strong-Buy Rating - MarketBeat
Jefferies raises Krystal Biotech stock price target to $310 on CF data By Investing.com - Investing.com South Africa
Jefferies raises Krystal Biotech stock price target to $310 on CF data - Investing.com Australia
Assessing Krystal Biotech (KRYS) Valuation As Investors Await CORAL-1 KB407 Interim Cystic Fibrosis Data - Sahm
Krystal Biotech Touts Positive KB407 CF Gene Therapy Data, Eyes Repeat Dosing and Registrational Path - Yahoo Finance
4.73%
0.92%
자본화:
|
볼륨(24시간):